Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Cell & Gene Therapies, RNA-based Therapies, mRNA Therapies, siRNA Therapies, Others), By Service (Process Development & Optimization Services, Manufacturing Services, Analytical & Quality Control Services, Others), By End Use (Pharmaceutical & Biotechnology Companies, Government & Academic Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Nucleic Acid Therapeutics CDMO Market Size

The global nucleic acid therapeutics CDMO market size was valued at USD 17.42 billion in 2025 and is projected to grow from USD 19.89 billion in 2026 to USD 57.46 billion by 2034, registering a CAGR of 14.18% during the forecast period from 2026 to 2034. North America dominated the nucleic acid therapeutics CDMO market with a market share of 41.03% in 2025.

The nucleic acid therapeutics CDMO market is witnessing strong expansion, driven by the rapidly growing pipeline of RNA- and gene-based therapies targeting oncology, rare diseases, and infectious conditions. As of 2025, the global pipeline includes over 1,200 RNA therapies and 2,000+ gene and cell therapy programs across development stages, along with more than 300 active RNA clinical trials, reflecting significant demand for specialized manufacturing and development support. The success of COVID-19 mRNA vaccines has accelerated the adoption of advanced platforms, such as siRNA and gene editing. Increasing outsourcing by biotech firms lacking GMP infrastructure, coupled with innovations in oligonucleotide synthesis and lipid nanoparticle delivery, is strengthening CDMO reliance. Strategic capacity expansions by Lonza Group and Thermo Fisher Scientific further support integrated, end-to-end service demand.

By Type

The RNA-based therapies segment dominated the nucleic acid therapeutics CDMO market in 2025, accounting for a 61.43% revenue share. The growth is driven by rapid expansion of mRNA vaccine platforms beyond infectious diseases into oncology, increasing demand for siRNA-based liver-targeted therapeutics with high delivery efficiency, and widespread adoption of lipid nanoparticle formulation systems enabling scalable RNA stabilization and clinical-grade manufacturing consistency.

The cell & gene therapies segment is expected to grow at a CAGR of 14.68% during the forecast period due to rapid expansion of AAV and lentiviral vector–based manufacturing requiring highly specialized CDMO platforms, increasing demand for autologous CAR-T production with complex patient-specific processing workflows, and rising adoption of CRISPR-based ex vivo therapies that need ultra-controlled GMP cleanroom environments and advanced viral vector analytics for safety and scalability.

Request Customizationto receive a tailored report.

By Service

Manufacturing services dominated the application segment with a share of 51.29% in 2025, due to rising GMP demand for oligonucleotides and mRNA requiring specialized synthesis platforms, increased outsourcing by biotech firms without in-house capacity, and expanding late-stage clinical pipelines needing scalable, compliant production. For example, Lonza supports large mRNA and RNA therapeutic programs through dedicated GMP suites and integrated production workflows.

The analytical & quality control services segment is expected to have the fastest growth, registering a CAGR of 14.88% during the forecast period. This growth is driven by increasing demand for high-resolution characterization of oligonucleotides and mRNA impurities using NGS analytics and rising regulatory requirements for detailed comparability and biosimilarity studies in nucleic acid therapeutics to detect modified nucleotide integrity and lipid nanoparticle payload consistency across GMP batches.

By End Use

The pharmaceutical & biotechnology companies segment is projected to grow at a CAGR of 15.34% during the forecast period. This growth is driven by increasing internal development of mRNA and oligonucleotide drug pipelines requiring outsourced CDMO support, rising adoption of platform-based drug discovery models enabling rapid nucleic acid candidate screening, and strong focus on rare disease and oncology biologics programs that demand scalable GMP manufacturing partnerships for accelerated clinical translation.

The government & academic research institutes segment is projected to grow at a CAGR of 15.71% during the forecast period due to large-scale national genome sequencing programs generating population-wide RNA and DNA reference libraries for precision medicine, rising publicly funded CRISPR and mRNA vaccine research initiatives targeting infectious and rare genetic diseases, and expanding translational research pipelines in universities.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America: Market Leadership through Strong CRISPR and RNA Clinical Pipelines and Increasing Genomic Funding

The North America nucleic acid therapeutics CDMO market, which captured 41.03% of global revenue in 2025, is propelled by strong CRISPR and RNA clinical pipelines requiring outsourced GMP production. It benefits from advanced mRNA vaccine platforms and high adoption of personalized oncology therapies needing rapid sequence design. The presence of leading CDMOs and biotech firms accelerates innovation, while robust regulatory frameworks support fast clinical translation and commercialization of nucleic acid drugs.

The US nucleic acid therapeutics CDMO market is growing due to federal funding programs supporting advanced genetic medicine manufacturing infrastructure and strong integration of academic medical centers with biotech startups. Increasing use of accelerated regulatory designations for rare disease oligonucleotide therapies also drives demand. Additionally, expansion of decentralized clinical trial networks enables faster patient-specific RNA therapy development and outsourcing to specialized CDMOs.

The Canadian nucleic acid therapeutics CDMO market is supported by strong provincial genomics initiatives, such as Genome Canada funding RNA and gene-editing research hubs, enabling early-stage outsourcing to specialized CDMOs. It benefits from close collaboration between universities like the University of Toronto and biotech startups developing oligonucleotide therapies for rare genetic disorders. Canada’s participation in cross-border North American biomanufacturing agreements supports clinical supply chain access for nucleic acid drugs and strengthens CDMO partnerships for scalable RNA production and translational research programs.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific: Fastest Growth Driven by Government-backed Biomanufacturing Initiatives and Increasing Clinical Trial Outsourcing

The Asia Pacific nucleic acid therapeutics CDMO market is expected to register the fastest growth with a CAGR of 16.56% during the forecast period due to strong government-backed biomanufacturing initiatives in countries like China, Japan, and South Korea, which actively fund RNA and gene therapy infrastructure. Increasing clinical trial outsourcing from Western biotech firms to APAC due to faster recruitment rates and lower operational costs is significantly accelerating CDMO demand across the region. The rising prevalence of genetic disorders, cancer, and infectious diseases across the region is increasing demand for advanced nucleic acid therapies.

The China nucleic acid therapeutics CDMO market is expanding due to strong government-backed biomanufacturing initiatives under the “Made in China 2025” and Shanghai Biopharma Hub programs supporting RNA and gene therapy infrastructure. It is further driven by large-scale CDMOs like WuXi AppTec enabling global oligonucleotide supply. Rising domestic cancer and genetic disease burden also accelerates demand for nucleic acid-based therapeutics development and outsourcing.

The Thailand nucleic acid therapeutics CDMO market is led by the development of ASEAN regional biomanufacturing harmonization programs, which position Thailand as a hub for cross-border RNA and oligonucleotide clinical supply within Southeast Asia. It is further supported by state-backed investment in cold-chain and biostorage logistics infrastructure, improving the stability and export readiness of sensitive nucleic acid products. Thailand’s growing public-private partnerships with hospitals such as Siriraj Hospital for genomic medicine programs are accelerating localized demand for nucleic acid therapeutics, strengthening development and outsourcing opportunities for CDMOs targeting regional precision medicine needs.

Competitive Landscape

The nucleic acid therapeutics CDMO market is partially consolidated and led by global players such as Lonza, Thermo Fisher Scientific, WuXi AppTec, and Catalent. These companies offer integrated services including oligonucleotide synthesis, mRNA manufacturing, plasmid DNA production, and analytical testing, and they compete through strong GMP infrastructure and end-to-end development capabilities. Specialized CDMOs like BioSpring, TriLink BioTechnologies, ST Pharm, and Nitto Avecia focus on high-purity RNA and oligo production with flexible and niche expertise. Smaller regional firms compete on cost and targeted services. Strategic partnerships with biotech and pharmaceutical companies support capacity expansion and strengthen positioning in advanced nucleic acid therapies.

List of Key and Emerging Players in Nucleic Acid Therapeutics CDMO Market